Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation

  • Molinero, Marta
  • Benítez, Iván
  • Perez Pons, Manel
  • Rodríguez Muñoz, Carlos
  • Gómez, Silvia
  • García Hidalgo, María
  • Sanchez Rodriguez, Miguel
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Torres Cortada, Gerard
  • Ayestarán, Jose Ignacio
  • Socias, Lorenzo
  • Zuil Moreno, María
  • Motos, Ana
  • Fernández Barat, Laia
  • Canseco, Joan
  • Nuñez, María Recuerda
  • Ortega, Alicia
  • Postigo, Tamara
  • Caballero, Jesús
  • Barberà, Carme
  • González, Jessica
  • Torres, Antoni
  • Barbé Illa, Ferran
  • Bermejo Martin, Jesús
  • Estella, Ángel
  • de Gonzalo Calvo, David
The application of microRNA (miRNA) profiling in respiratory biospecimens, particularly bronchial aspirate (BAS), remains underexplored. Here, we aimed to validate and refine miRNA quantification in BAS samples to establish its suitability for molecular phenotyping. This was a multicenter study including 288 COVID-19 patients on invasive mechanical ventilation. Respiratory biospecimens included BAS, tracheal aspirate, and bronchoalveolar lavage fluid samples. A predesigned miRNA panel was evaluated using RT-qPCR. Biomarker evaluation and functional assessment were subsequently conducted. An initial technical validation phase corroborated the reproducibility of miRNA profiling in BAS samples. Comparative analyses of miRNA expression profiles across respiratory samples revealed distinct miRNA patterns among biospecimens. In the biomarker analysis, two miRNA ratios, miR-34c-5p/miR-34a-5p and miR-34c-5p/miR-125b-5p, were inversely associated with intensive care unit (ICU) survival (hazard ratio [HR]: 0.18 and 0.17, respectively) during the discovery phase. Risk and survival analyses in the test phase confirmed the reproducibility of the miR-34c-5p/miR-34a-5p ratio (hazard ratio [HR] = 0.17). Functional analyses revealed the utility of miRNA profiling in BAS for identifying pathogenic pathways and developing therapeutic targets. Overall, these findings position miRNA profiling in BAS samples as a valuable approach for biomarker discovery, identification of pathophysiological mechanisms, and development of targeted pulmonary therapies., This work was supported by the Instituto de Salud Carlos III de Madrid (COV20/00110), cofunded by the European Union and Centro de Investigación Biomedica En Red—En fermedades Respiratorias (CIBERES). CIBERES (CB07/06/2008) is an initiative of the Instituto de Salud Carlos III. Further support was provided by the Programa de ciones “estar preparados” UNESPA (Madrid, Spain). F.B. is supported by the ICREA Academia Program. D.d.G.-C. has received financial support from Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041), cofunded by the European Union. M.M. (PFIS 2021: FI21/00187) and M.P.-P. (PFIS 2023: FI23/00022) are the recipients of a doctoral fellowship from Instituto de Salud Carlos III and cofunded by the European Union. MCGH held a predoctoral fellowship from Ayudas al Personal Investigador en Formación from IRBLleida/Diputación de Lleida. C.R. is supported by Departament de Salut (Pla Estratègic de Recerca i Innovació en Salut (PERIS): SLT028/23/000191) and programa predoctoral AGAUR-FI ajuts (2025 FI-2 00863) Joan Oró de la Secretaria d’Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya i del Fons Europeu Social Plus. We want to particularly acknowledge the patients and the Biobanco A Coruña—Área Sanitaria A Coruña y Cee—SERGAS—INIBIC (B.0000796, PT17/0015/0032) and IdISBa Biobank and CIBERES Pulmonary Biobank Consortium (PT17/0015/0001), both integrated in the Spanish National Biobanks Network financed by the Carlos III Health Institute and the Units of Intensive Care, Clinical Analysis and Pulmonology of Hospital Universitario Son Espases, and Hospital Son Llatzer for their collaboration. This work was supported by the IRBLleida Biobank (B.000682) and the Biobank and Biomodels Platform ISCIII PT23/00032. Human sample manipulation was performed at the Cell Culture Facility, Universitat de Lleida (Lleida, Catalonia, Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation

  • Molinero, Marta
  • Benítez, Iván
  • Perez Pons, Manel
  • Rodríguez Muñoz, Carlos
  • Gómez, Silvia
  • García Hidalgo, María
  • Sanchez Rodriguez, Miguel
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Torres Cortada, Gerard
  • Ayestarán, Jose Ignacio
  • Socias, Lorenzo
  • Zuil Moreno, María
  • Motos, Ana
  • Fernández Barat, Laia
  • Canseco, Joan
  • Nuñez, María Recuerda
  • Ortega, Alicia
  • Postigo, Tamara
  • Caballero, Jesús
  • Barberà, Carme
  • González, Jessica
  • Torres, Antoni
  • Barbé Illa, Ferran
  • Bermejo Martin, Jesús
  • Estella, Ángel
  • de Gonzalo Calvo, David
The application of microRNA (miRNA) profiling in respiratory biospecimens, particularly bronchial aspirate (BAS), remains underexplored. Here, we aimed to validate and refine miRNA quantification in BAS samples to establish its suitability for molecular phenotyping. This was a multicenter study including 288 COVID-19 patients on invasive mechanical ventilation. Respiratory biospecimens included BAS, tracheal aspirate, and bronchoalveolar lavage fluid samples. A predesigned miRNA panel was evaluated using RT-qPCR. Biomarker evaluation and functional assessment were subsequently conducted. An initial technical validation phase corroborated the reproducibility of miRNA profiling in BAS samples. Comparative analyses of miRNA expression profiles across respiratory samples revealed distinct miRNA patterns among biospecimens. In the biomarker analysis, two miRNA ratios, miR-34c-5p/miR-34a-5p and miR-34c-5p/miR-125b-5p, were inversely associated with intensive care unit (ICU) survival (hazard ratio [HR]: 0.18 and 0.17, respectively) during the discovery phase. Risk and survival analyses in the test phase confirmed the reproducibility of the miR-34c-5p/miR-34a-5p ratio (hazard ratio [HR] = 0.17). Functional analyses revealed the utility of miRNA profiling in BAS for identifying pathogenic pathways and developing therapeutic targets. Overall, these findings position miRNA profiling in BAS samples as a valuable approach for biomarker discovery, identification of pathophysiological mechanisms, and development of targeted pulmonary therapies., This work was supported by the Instituto de Salud Carlos III de Madrid (COV20/00110), cofunded by the European Union and Centro de Investigación Biomedica En Red—En fermedades Respiratorias (CIBERES). CIBERES (CB07/06/2008) is an initiative of the Instituto de Salud Carlos III. Further support was provided by the Programa de ciones “estar preparados” UNESPA (Madrid, Spain). F.B. is supported by the ICREA Academia Program. D.d.G.-C. has received financial support from Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041), cofunded by the European Union. M.M. (PFIS 2021: FI21/00187) and M.P.-P. (PFIS 2023: FI23/00022) are the recipients of a doctoral fellowship from Instituto de Salud Carlos III and cofunded by the European Union. MCGH held a predoctoral fellowship from Ayudas al Personal Investigador en Formación from IRBLleida/Diputación de Lleida. C.R. is supported by Departament de Salut (Pla Estratègic de Recerca i Innovació en Salut (PERIS): SLT028/23/000191) and programa predoctoral AGAUR-FI ajuts (2025 FI-2 00863) Joan Oró de la Secretaria d’Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya i del Fons Europeu Social Plus. We want to particularly acknowledge the patients and the Biobanco A Coruña—Área Sanitaria A Coruña y Cee—SERGAS—INIBIC (B.0000796, PT17/0015/0032) and IdISBa Biobank and CIBERES Pulmonary Biobank Consortium (PT17/0015/0001), both integrated in the Spanish National Biobanks Network financed by the Carlos III Health Institute and the Units of Intensive Care, Clinical Analysis and Pulmonology of Hospital Universitario Son Espases, and Hospital Son Llatzer for their collaboration. This work was supported by the IRBLleida Biobank (B.000682) and the Biobank and Biomodels Platform ISCIII PT23/00032. Human sample manipulation was performed at the Cell Culture Facility, Universitat de Lleida (Lleida, Catalonia, Spain).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide -[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Rull, Anna|||0000-0002-8907-7754
  • Aldana-Ramos, Joile
  • Santos, David|||0000-0003-1157-4969
  • Puig, Nuria
  • Farre-Cabrerizo, Nuria
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pérez, Antonio|||0000-0001-5528-1143
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Mimetic peptides are potential therapeutic agents for atherosclerosis. -[113-122]apolipoprotein (apo) J (-[113-122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of -[113-122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with -[113-122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with -[113-122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of -[113-122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from -[113-122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with -[113-122]apoJ. Our results demonstrate that the -[113-122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile

  • Rossi-Herring, Guido|||0000-0003-1454-0916
  • Belmonte, Thalia|||0000-0003-1241-6073
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Benitez, Sonia|||0000-0003-3565-0743
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Crespo García, Javier|||0000-0001-8248-0172
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the bibliography on this topic is scarce and shows a high variability between independent investigations. In addition, the miRNA profiles of the LDL and VLDL fractions have not been completely elucidated. Here, we profiled the human circulating lipoprotein-carried miRNome. Lipoprotein fractions (VLDL, LDL and HDL) were isolated from the serum of healthy subjects by ultracentrifugation and purified by size-exclusion chromatography. A panel of 179 miRNAs commonly expressed in circulation was evaluated in the lipoprotein fractions using quantitative real-time PCR (qPCR) assays. A total of 14, 4 and 24 miRNAs were stably detected in the VLDL, LDL and HDL fractions, respectively. VLDL- and HDL-miRNA signatures were highly correlated (rho 0.814), and miR-16-5p, miR-142-3p, miR-223-3p and miR-451a were among the top 5 expressed miRNAs in both fractions. miR-125a-5p, miR-335-3p and miR-1260a, were detected in all lipoprotein fractions. miR-107 and miR-221-3p were uniquely detected in the VLDL fraction. HDL showed the larger number of specifically detected miRNAs (n = 13). Enrichment in specific miRNA families and genomic clusters was observed for HDL-miRNAs. Two sequence motifs were also detected for this group of miRNAs. Functional enrichment analysis including the miRNA signatures from each lipoprotein fraction suggested a potential role in mechanistic pathways previously associated with cardiovascular disease: fibrosis, senescence, inflammation, immune response, angiogenesis, and cardiomyopathy. Collectively, our results not only support the role of lipoproteins as circulating miRNA carriers but also describe for the first time the role of VLDL as a miRNA transporter.